Literature DB >> 2467807

The late effects of cis-platinum on renal function.

C R Hamilton1, J M Bliss, A Horwich.   

Abstract

The combination of bleomycin, etoposide and cis-platinum (BEP) is an effective treatment for germ cell tumours. To help define the role of recently developed non-nephrotoxic analogues of cis-platinum we have analysed the long term renal damage caused by this agent. We report on 22 patients studied 8-60 months following BEP chemotherapy. In the 17 cases with no pre-chemotherapy renal impairment there was a fall in mean glomerular filtration rate from 132 ml/min (95% confidence interval 123, 141) pre-chemotherapy to 103 ml/min (95% confidence interval 94, 113) on late follow up. The overall pattern is one of initial fall of glomerular filtration rate during chemotherapy, and no consistent evidence of late recovery or further deterioration; considerable individual variation is observed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2467807     DOI: 10.1016/0277-5379(89)90006-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  16 in total

1.  Cisplatin-induced reductions in renal functional reserve uncovered by unilateral nephrectomy: an experimental study in the pig.

Authors:  M E Robbins; D Campling; E Whitehouse; J W Hopewell; A Michalowski
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Acute tubular necrosis following high-dose cyclosporine A therapy.

Authors:  P Shechter
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Gamma-glutamyl transpeptidase-deficient mice are resistant to the nephrotoxic effects of cisplatin.

Authors:  M H Hanigan; E D Lykissa; D M Townsend; C N Ou; R Barrios; M W Lieberman
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  A randomized trial comparing the nephrotoxicity of cisplatin/ifosfamide-based combination chemotherapy with or without amifostine in patients with solid tumors.

Authors:  J T Hartmann; L M Fels; S Knop; H Stolt; L Kanz; C Bokemeyer
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

5.  Long-term studies of cisplatin-induced reductions in porcine renal functional reserve.

Authors:  M E Robbins; T B Bywaters; R S Jaenke; J W Hopewell; L M Matheson; P Tothill; E Whitehouse
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

6.  Cisplatin therapy in infants: short and long-term morbidity.

Authors:  P R Brock; E C Yeomans; S C Bellman; J Pritchard
Journal:  Br J Cancer Suppl       Date:  1992-08

Review 7.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

8.  The relative nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat.

Authors:  M M Jones; M A Basinger; J A Beaty; M A Holscher
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

9.  Long-Term Renal Outcomes after Cisplatin Treatment.

Authors:  Sheron Latcha; Edgar A Jaimes; Sujata Patil; Ilya G Glezerman; Swati Mehta; Carlos D Flombaum
Journal:  Clin J Am Soc Nephrol       Date:  2016-04-12       Impact factor: 8.237

10.  Long-term complications of platinum-based chemotherapy in testicular cancer survivors.

Authors:  J H Oh; D D Baum; S Pham; M Cox; S T Nguyen; J Ensor; I Chen
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.